Gt Biopharma, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
GT Biopharma Director David C. Mun-Gavin acquired 31,250 options to purchase common stock at an exercise price of $1.33.
NASDAQ
GT Biopharma's CEO and Director, Michael Martin Breen, acquired 300,000 options to purchase common stock at an exercise price of $1.33 per share.
NASDAQ
GT Biopharma's Chief Financial Officer, Alan Urban, was granted 100,000 stock options with an exercise price of $1.33, vesting quarterly over two years.
NASDAQ
GT Biopharma Director Charles J. Casamento acquired 62,500 stock options, fully vested and exercisable, with an exercise price of $1.33.
NASDAQ
GT Biopharma Director Hilary Kramer reported the acquisition of 31,250 stock options with an exercise price of $1.33.
NASDAQ
Alan Urban, CFO of GT Biopharma, acquired options to purchase 23,335 shares of common stock on October 17, 2024.